Lv3
275 积分 2021-09-16 加入
The year in Cardiovascular Medicine 2025: the top 10 papers in dyslipidaemias
4小时前
已完结
Systematic review and model-based analysis to identify whether renal safety risks of URAT1 inhibitors are fully determined by uric acid-lowering efficacies
12天前
已完结
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout
12天前
已完结
[Acceptability and tolerance of sodium valproate, a new sustained-action granule formulation, in monotherapy for epileptic children from 3 years old]
1个月前
已完结
Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia
4个月前
已完结
Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy
4个月前
已完结
Efficacy for LDL-C-lowering and safety of pemafibrate extended-release formulation in patients with statin-intolerant hypercholesterolemia: A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group trial
4个月前
已完结
Pemafibrate for hypertriglyceridemia: a meta-analysis of randomized controlled trials evaluating efficacy and safety outcomes
4个月前
已完结
Factors Affecting Tautomeric Phenomenon of a Novel Potent Immunosuppressant (FK506) on the Design for Injectable Formulation
6个月前
已完结
皖公网安备34019202002308
